错配无关供者造血干细胞移植中的感染负担:ACCESS 试验结果
ACCESS 试验纳入 268 例接受错配无关供者造血干细胞移植的成人患者,采用标准剂量移植后环磷酰胺预防移植物抗宿主病。共记录 465 例 CTCAE 2–5 级感染,183 例(68%)发生感染,21 例(7.8%)死于感染。多变量分析显示急性移植物抗宿主病与感染显著相关。
要点
- 标准剂量 PTCy 方案下 MMUD HCT 感染负担显著,64% 感染发生在移植后 100 天内。
- 感染密度在 0–30 天最高,且不因预处理强度或 HLA 错配程度而异。
- 急性 GVHD 是多变量分析中与感染显著相关的因素。
核心结论
- 标准剂量 PTCy 的 MMUD HCT 感染负担显著,不因预处理强度和供者 HLA 错配水平而异,可作为降低感染负担试验的基准。
研究设计与样本
- ACCESS 试验为前瞻性研究,纳入 268 例接受 MMUD HCT 的成人血液系统恶性肿瘤患者,采用标准剂量 PTCy 预防 GVHD。
- 感染按 CTCAE 5.0 标准分级,分析感染密度、累积发病率和病原体类型。
主要发现
- 183 例(68%)成人发生 465 例 CTCAE 2–5 级感染,其中 176 例(38%)为显著或危及生命感染。
- 296 例(64%)感染发生在移植后 100 天内,0–30 天感染密度显著高于其他时段。
- 感染密度、病原体类型和分离株在预处理强度和 HLA 错配水平间相似。
- 多变量分析显示急性 GVHD 与感染显著相关。
- 21 例(7.8%)患者死于感染。
临床怎么用
- 在 MMUD HCT 采用标准剂量 PTCy 时,应关注早期(尤其 0–30 天)感染负担,并加强急性 GVHD 患者的感染监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) has emerged as an effective therapy for adult patients with hematologic malignancies. The MMUD ACCESS trial, which incorporated posttransplant cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis, demonstrated a combined overall survival of 81% in enrolled patients, 59% of whom were from ethnically diverse groups. Given that PTCy is also associated with significant bacterial and viral infections, we defined infection burden in the full adult cohort (N = 268) using infections graded according to an international standard (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0). Infection density (number of infections per 100 days at risk), cumulative incidence of infection, and frequency of pathogen types were categorized by post-HCT time, conditioning intensity, level of donor HLA mismatch, and presence of acute GvHD (aGvHD). Of 465 CTCAE grade 2 to 5 infections recorded in 183 (68%) adults, 176 (38%) were significant or life-threatening, and most (296 [64%]) occurred within the first 100 days. Infection density at days 0 to 30 was significantly higher than at other times and was similar by conditioning and level of HLA mismatch, as were pathogen types and isolates. Multivariable analysis showed that aGvHD is significantly associated with infection. Finally, 21 (7.8%) patients died of infection. Results show significant infection burden using standard-dose PTCy in the MMUD HCT setting, irrespective of conditioning and level of donor HLA mismatch, and serve as a benchmark for trials investigating reducing infection burden after MMUD HCT. This trial was registered at www.clinicaltrials.gov as NCT04904588.
引用
- Auletta JJ, Stanek J, Bo-Subait S, et al. Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial. Blood Adv. 2026. PMID: 42448319. doi:10.1182/bloodadvances.2026020882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。